CN106148563A - The biomarker of carcinoma of prostate - Google Patents
The biomarker of carcinoma of prostate Download PDFInfo
- Publication number
- CN106148563A CN106148563A CN201610872064.XA CN201610872064A CN106148563A CN 106148563 A CN106148563 A CN 106148563A CN 201610872064 A CN201610872064 A CN 201610872064A CN 106148563 A CN106148563 A CN 106148563A
- Authority
- CN
- China
- Prior art keywords
- gene
- prostate cancer
- prostate
- pseudogene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses for detecting prostate cancer marker, the described label one or more genes in following EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1.The present invention further discloses the application in preparing prostate cancer diagnosis and prognosis product of the described label.The invention also discloses a kind of prostate cancer diagnosis or prognosis evaluation reagent kit, described test kit includes one or more groups the primer sequence in specific amplification EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1.The present invention utilizes one or more gene can not only accomplish fast and effectively to detect in early days as label joint-detection carcinoma of prostate, prognosis evaluation, its degree of accuracy is greatly improved, and provides therapy target and important evidence for the clinical practice such as gene therapy, Drug therapy.
Description
Technical field
The present invention relates to biomedicine field, be specifically related to relating to prostate cancers because of expression to diagnose cancer also
The products application of monitoring therapeutic effect.
Background technology
Carcinoma of prostate is one of common male reproductive system malignant tumor.In world wide, prostate-cancer incidence exists
Occupying second in all malignant tumor of male, the sickness rate in U.S.'s carcinoma of prostate alreadys more than pulmonary carcinoma, becomes first harm
The tumor of men's health.The sickness rate of Asia carcinoma of prostate is well below American-European countries, but presents ascendant trend in recent years, and increases
Long rapider than European and American developed countries.Patients with prostate cancer is mainly elderly men, typically at 50 years old with sequela, and 95%
Being born in the elderly men of more than 60 years old, incidence rate increases the most with age.Carcinoma of prostate is the most without any disease
Shape, even if uncomfortable, is also not enough to cause the attention of patient, when tumor increases urethra, the most often increases with prostate
Life is obscured mutually.First patient in China about 80% finds that metastasis focus just finds carcinoma of prostate.Now, pathological changes has reached late
Phase, prognosis mala.
The clinical diagnostic modalities of carcinoma of prostate currently mainly has serum PSA (PSA) detection, rectum to refer to
Inspection, the detection of endorectal ultrasonography ripple, living tissue pathologic finding etc..PSA (Prostate Specific Antigen) is prostata tissue
Specific antigen, is understood PSA by prostatic anatomical structure and enters in blood and urine by prostate duct, some cases or
Under physiological conditions, PSA can enter in blood, such as prostatitis, urine retention, prostate infection, prostatic hyperplasia and prostate
By detection Serum PSA level, cancers etc., therefore predict that carcinoma of prostate has certain false positive rate.From the beginning of 1991, inspection
Surveying PSA content in serum and be used for predicting carcinoma of prostate, it is positive that content is considered carcinoma of prostate higher than 4ng/mL, sensitivity 79%,
Specificity 20%-59%, average sensitivity about 33%, in concentration 4-10ng/mL gray area part, specificity is minimum, at this moment
Generally require and be determined by invasive aspiration biopsy, bring considerable distress and spirit and financial burden to patient.So
PSA can not be preferably as the mark of diagnosis of prostate cancer.Digital rectal examination is the method for practicality the simplest, most economical, main
The forefinger of doctor to be passed through touches prostate, in order to find a lot of asymptomatic patients with prostate cancer, it is possible to obtains and examines in early days
Chance that is disconnected and that effect a radical cure.But all there is limitation in above method.The limitation of such as digital rectal examination is mainly at 4 aspects: (1)
When patient's prostate lump is little, easy to cause missed diagnosis；(2) enlargement of some patients carcinoma of prostate is inconspicuous, but is already belonging to late period, is difficult to root
Control；(3) patient's rectum can not use this to detect when having illness；(4) may have during doctors experience deficiency fail to pinpoint a disease in diagnosis or mistaken diagnosis can
Energy.
Pseudogene has similar sequence to normal gene, but deposits difference structurally with normal gene.These are poor
The different nucleotide deletion being included in varying degree on different parts or insertion, at gene intron and exon bonding pad occurred sequence
, containing termination codon in the middle of coded sequence, or there is defect etc. in transcripting starting area in row change.These changes make this type of base
Because of can not transcription and translation, or produce defective protein thus lose original biological function.For a long time, people recognize
It is the most normally, but there is no function " death gene " for pseudogene, is genome evolution " fossil record ".But in recent years
Coming, the discussion about pseudogene is increasing, and increasing test confirms that pseudogene can be transcribed and express.Pseudogene exists
The aspect such as gene expression regulation, genome evolution plays an important role.
Currently for Late-stage Prostate Cancer patient, the weak effect of operative treatment, great majority use Drug therapy.According to
The different state of an illness can use chemotherapy, fluconazole ear drops, radionuclide internal radiotherapy and various therapy
Integrated application etc..But, radiotherapy and chemotherapy medicine acts not only on tumor, it is also possible to act on the tissue of tumor adjacent healthy, thus
While killing tumor, also bring the biggest side effect to body, finally affect the therapeutic effect to tumor.Therefore, originally
Field is in the urgent need to developing the Specific marker of carly fruit drop carcinoma of prostate, and develops the targeted drug of carcinoma of prostate.
Summary of the invention
In order to realize the early diagnosis of carcinoma of prostate, prognosis evaluation, individualized treatment, an object of the present invention is to carry
For the label for detecting carcinoma of prostate.
The two of the purpose of the present invention are to provide described label in preparing prostate cancer diagnosis and prognosis product
Application.
The three of the purpose of the present invention are to be to provide a kind of prostate cancer diagnosis or prognosis evaluation reagent kit.
For achieving the above object, present invention firstly provides for detecting prostate cancer marker, described label is selected from
Following EFCAB10 (NR_027068.1, lncRNA), MBL1P (NR_002724.2, pseudogene), PPIEL (NR_
003929.2, pseudogene), RAET1K (NR_024045.1, pseudogene), RPL13AP6 (NR_026715.1,
Pseudogene) the one or more genes and/or in THSD1P1 (NC_000013.11, pseudogene).
Preferably, described gene equal down-regulated expression in prostate cancer tissue.
Further, the invention provides described label answering in preparing prostate cancer diagnosis and prognosis product
With.
Preferably, described diagnosis and prognosis monitor for diagnosis, curative effect evaluation or transfer and relapse.
Preferably, described product includes detectable or test kit.
Preferably, described detectable includes treating test sample with fluorescence quantifying PCR method, gene chip or RNA order-checking detection
In product, the relative amount of said gene carrys out diagnosis of prostate cancer.
Preferably, described gene chip includes that solid phase carrier and the oligonucleotide being fixed on described solid phase carrier are visited
Pin, described oligonucleotide probe includes the part or all of sequence specifically corresponding to gene nucleotide recited above.
Preferably, the relative amount of described gene is the carcinoma of prostate gene expression dose expression compared to comparison.
Preferably, described testing sample includes cell tissue sample and the blood sample of experimenter；Described cell tissue sample
Product include prostate cancer tissue samples or cancer beside organism；Described prostate cancer tissue sample include treatment before or treatment after group
Knit sample；Described comparison is cancer beside organism's sample；Described cancer beside organism is normal structure.
Preferably, described treatment includes using surgical intervention, chemotherapy, radiotherapy, Drug therapy or a combination thereof.
Preferably, the expression of described detection gene includes detecting transcript level.
Further, the present invention provides a kind of prostate cancer diagnosis or prognosis evaluation reagent kit, and described test kit includes spy
One or more groups primer sequence in specific amplification EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1
Row.
Preferably, described primer sequence includes:
EFCAB10:SEQ IDNO.1 and 2；
MBL1P:SEQ IDNO.3 and 4；
PPIEL:SEQ IDNO.5 and 6；
RAET1K:SEQ IDNO.7 and 8；
RPL13AP6:SEQ IDNO.9 and 10；
And/or THSD1P1:SEQ IDNO.11 and 12.
Preferably, described test kit also includes 10 × Buffer, dNTP, MgCl2, Taq enzyme and SYBR Green fluorescence dye
Material.Described test kit contains the normal prostata tissue of people or the total serum IgE of cell or DNA.
Further, there is the in vitro method of carcinoma of prostate in the present invention in providing a kind of experimenter of detection.Described method bag
Including and determine that the expression of one or more genes is to obtain measured value in first sample of experimenter, described gene selects
From: EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1.And by described measured value and reference value
Compare.Significantly lower than reference value, measured value shows that described experimenter suffers from carcinoma of prostate.Described reference level is normal thin
The level of said gene in born of the same parents.
Further, the present invention provides a kind of assessment in vitro method to the prostate cancer therapy effect of experimenter.Described
Method include the relative expression's content determining the one or more genes from experimenter to obtain the first value, described gene select
From: EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1.Experimenter is implemented treatment of cancer；Determine
In the subsequent sample obtained by experimenter behind, relative expression's content of described one or more homologous geneses is controlled to obtain
Treatment value；With by the first described value compared with described therapeutic value.Assessment criterion of therapeutical effect is set to, when therapeutic value is higher than the first value
When 10%, show that described treatment is effective, during less than or equal to 10%, illustrate that described treatment is invalid.
Preferably, first described and subsequent sample is known or under a cloud comprises prostate cancer tissue or cell, example
The blood sample comprising circulation prostate gland cancer cell (CTC) as is known or under a cloud, known or under a cloud containing prostatitis
The biopsy samples of adenocarcinoma cell.
Beneficial effects of the present invention is as follows:
The invention discloses one group of gene relevant to carcinoma of prostate, and the expression being further characterized by these genes exists
Expression in prostate cancer is lowered.One or more gene association detection carcinoma of prostate is utilized to do fast and effectively
To detection, prognosis evaluation in early days, its degree of accuracy is greatly improved, and provides for the clinical practice such as gene therapy, Drug therapy
Therapy target and important evidence.
Accompanying drawing explanation
Fig. 1 be respectively EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and THSD1P1 at prostate cancer tissue and
The expression of cancer beside organism.
Detailed description of the invention
Following example are used for illustrating the present invention, but are not limited to the scope of the present invention.If not specializing, embodiment
The conventional means that technological means used by is well known to those skilled in the art, reagent used can be commercially available.
The experimental technique of unreceipted actual conditions, usually this area conventional method in embodiment, as according to normal condition
Such as Sambrook et al., molecular cloning, the described condition in laboratory manual (third edition) (Science Press, 2002), or according to
Condition proposed by reagent manufacturing firm.
The present inventor carries out high-flux sequence, by biology to prostate cancer tissue sample and cancer beside organism's sample
Informatics Method carries out genescreen, selects 6 candidate genes: EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and
THSD1P1, not about the report that said gene is relevant with carcinoma of prostate in existing research, further, inventor is carried out
Molecular biology method checking is it was confirmed said gene down-regulated expression in prostate gland cancer cell.
EFCAB10 (EF-hand calcium binding domain 10, EF-hand-type calcium binding structural domain) is a kind of
Long-chain non-coding RNA (long noncoding RNA, lncRNA), is positioned on No. 7 chromosomes.Research finds that EFCAB10 is in first
Shape papillocarcinoma of breast and esophageal carcinoma up-regulated, may occur relevant to thyroid papillary carcinoma and the esophageal carcinoma.
MBL1P (mannose binding lectin 1, pseudogene, mannose binding lectin 1, pseudogene),
It is positioned on No. 10 chromosome.Mankind MBL (mannose binding lectin, mannose binding lectin) has two bases
Cause, wherein MBL1 is pseudogene, and only MBL2 can coded protein.
PPIEL (peptidylprolyl isomerase E like pseudogene, peptidyl prolyl isomerase E class
Pseudogene) it is positioned on No. 1 chromosome, it is the pseudogene relevant to PPIE genetic transcription.PPIEL is at nonsmall-cell lung cancer
(NSCLC) down-regulated expression in.
RAET1K (retinoic acid early transcript 1K pseudogene, retinoic acid early transcription 1k
Pseudogene) it is positioned on No. 6 chromosomes.
RPL13AP6 (ribosomal protein L13a pseudogene 6, ribosomal protein L 13a pseudogene 6) position
On No. 10 chromosomes.
THSD1P1 (thrombospondin type 1 domain containing 1pseudogene 1, platelet
Reactive protein 1 type territory comprises 1 pseudogene 1) it is positioned on No. 13 chromosomes, it is the pseudogene of THSD1 genetic transcription.
The described gene of the present invention be before making the present invention it is known that essential information can be found in Genbank, come
Come from human genome.
The present invention also use RT-PCR method detection said gene in prostate cancer tissue and the expression of Carcinoma side normal tissue,
And demonstrate said gene down-regulated expression in carcinoma of prostate.
Terminology used in the present invention " down-regulated expression " refers to the sequence corresponding to expressed gene, wherein the measurement card of sequence amount
Bright, and from normal individual or from being determined by stages of prostate cancer the individuality identifying morbid state different with carcinoma of prostate
Same gene in the biological sample separated is compared, and described gene is from suffering from carcinoma of prostate or being determined by stages of prostate cancer
Carcinoma of prostate identified that the expression in the biological sample separated in the individuality of morbid state reduces.According to the present invention,
" down-regulated expression " refer to by the inventive method intensity for hybridization measure at least 1%, 2%, 3%, 4%, 5%, 6%, 7%,
8%, 9%, 10% or more express reduction, such as 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more
Low.
In the present invention, " prognosis " refer to that cancer patient is being pressed down by operation, chemotherapy, Drug therapy or a combination thereof process etc.
Process after system or alleviation tumor growth or result.Prognosis can be to be processed by operation, chemotherapy, Drug therapy or a combination thereof to press down
System or life state when alleviating after tumor growth 1,2,3,4,5,6,7,8,9,10,15,20 years or more long.Prognosis can be passed through
Check that mark is assessed, described label selected from following EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or
One or more genes in THSD1P1.Prognosis evaluation can be performed such that according to mark with or without, or raise or
Reduce, determine that the prognosis of patient is good or bad, or determine the probability of good prognosis or poor prognosis.
Embodiment 1 high-flux sequence screening difference expression gene
1, sampling
In BJ Union Hospital's urological surgery, tissue specimen is obtained during taking in December, 2015 in October, 2011 to
27 examples, all specimen all confirm through pathological examination, and wherein cancer beside organism's sample 8 example, carcinoma of prostate specimen 19 example, after numbering
Put-80 DEG C of cryogenic refrigerators to preserve.
2, tissue samples is carried out Total RNAs extraction
UseReagent (invitrogen, article No. 15596-018) carries out sample rna extraction, experiment behaviour
Making to carry out by product description, concrete operations are as follows:
After collecting sample, frozen mortar tissue being put into pre-cooling after liquid nitrogen, taking-up is ground, sample to be organized
After this is powdered:
1. Trizol, room temperature preservation 5 minutes are added；
2. adding chloroform 0.2mL, use forced oscillation centrifuge tube, fully mix, ambient temperatare puts 5 minutes-10 minutes；
3. 12000rpm high speed centrifugation draws upper strata aqueous phase (inhale 70%) in another new centrifuge tube pipe after 15 minutes, notes
It is not drawn onto the protein substance between two-layer aqueous phase.Move into new pipe, add isopyknic-20 DEG C of pre-cold isopropanols, the most reverse
Mixing, is placed in 10 minutes on ice；
4. 12000rpm carefully discarded supernatant at a high speed after 15 minutes, added 75% in the ratio of 1mL/mL Trizol
Paint precipitation (4 DEG C of preservations) washed by DEPC ethanol, washes paint precipitate, vibration mixing, 12000rpm high speed centrifugation 5 minutes at 4 DEG C；
5. discard ethanol liquid, ambient temperatare put 5 minutes fully to dry precipitation, add the water dissolution that processed of DEPC and sink
Form sediment；
6. RNA purity and concentration are measured with Nanodrop2000 ultraviolet spectrophotometer, frozen in-80 DEG C.RNA mass is sentenced
Calibration standard: the OD260/OD280 value of RNA sample is between 1.7-2.2；Total serum IgE electrophoresis pattern has 28S, 18S band clearly；
70 DEG C of water bath heat preservation electrophoresis patterns after 1 hour and the collection of illustrative plates no significant difference before water bath heat preservation.
3, the quality analysis of RNA sample
RNA extract after agarose gel electrophoresis, from electrophoresis result can with preliminary judgement extract RNA sample up-to-standard with
No, if to may be used for further transcriptome analysis.And then by NanoDrop1000 spectrophotometer detection RNA sample
Extraction situation, the sample requirement of RNA-seq order-checking: OD260/OD280 is 1.8-2.2.
4, high-flux sequence
Order-checking platform is the HiSeq 2500 high-flux sequence platform of Illumina company, carries out the high flux transcript profile degree of depth
Order-checking, after order-checking, we use Fast-QC (http://www.bioinformatics.babraham.ac.uk/projects/
Fastqc/) software carries out total evaluation to the quality of sequencing data, and the mass value including base is distributed, and the position of mass value is divided
Cloth, G/C content, PCR duplication content, the frequency etc. of kmer.When differential genes expression analysis, according to obtaining
FPKM value, use internationally recognized algorithm EBSeq to carry out differential screening.Wherein, during screening, LOG2FC>1 or<-1, FDR<
0.05.In order to be better understood from the function of difference expression gene, we difference expression gene has been carried out Gene Ontology and
Signal path is analyzed, and difference expression gene is carried out functional annotation, the result analyzed in view of data above, in conjunction with document we
Having screened differential expression EFCAB10, MBL1P, PPIEL, RAET1K, THSD1P1 and RPL13AP6 gene, said gene is in prostatitis
Down-regulated expression in adenocarcinoma tissue sample.
Expression conditions in embodiment 2RT-PCR checking prostate cancer tissue and cancer beside organism
1, material
During prostate cancer tissue sample 34 example and cancer beside organism's sample 8 example take from BJ Union Hospital 2011 to 2015 years
Carcinoma of prostate sample in urological surgery, is grouped it and numbers.All sample standard deviations confirm through pathological examination.
2, method
2.1 pairs of tissue samples carry out Total RNAs extraction, with the extracting method of embodiment 1.
2.2 reverse transcription synthesis cDNA
UseIII Reverse Transcriptase (invitrogen, article No. 18080-044)
Carrying out cDNA reverse transcription, experimental implementation is carried out by product description, and concrete operations are as follows:
Use Reverse Transcriptase kit, with RT Buffer, l μ g total serum IgE is carried out converse record and synthesize cDNA.Use 25 μ L
Reaction system, each sample takes 1 μ g total serum IgE as template ribonucleic acid.It is standby that-20 DEG C of refrigerators are put in the cDNA preservation obtained.
2.3Real-Time PCR
2.3.1 instrument and the method for analysis
With ABI 7500 type quantitative real time PCR Instrument, use 2-ΔΔCtMethod carries out data relative quantitative assay.
2.3.2 design of primers
Use online primer-design software, gene order with reference to NCBI:EFCAB10 (NR_027068.1, ncRNA),
MBL1P (NR_002724.2, pseudogene), PPIEL (NR_003929.2, pseudogene), RAET1K (NR_
024045.1, pseudogene), RPL13AP6 (NR_026715.1, pseudogene) and/or THSD1P1 (NC_
000013.11, pseudogene), interior participation in the election GAPDH, synthesized by invitrogen company after design of primers.Concrete primer sequence
As follows:
Table 1 primer sequence
Operating process is as follows:
Table 2 Real Time reaction system
| Component | Addition |
| 2×mix | 10μL |
| Forward primer (10uM) | 0.5μL |
| Downstream primer (10uM) | 0.5μL |
| Template | 2μL |
| Add sterile purified water | To 25 μ L |
(1) reaction system: use PowerGreen PCR Master Mix (invitrogen, article No.
4367659) expanding, experimental implementation is carried out by product description.
Amplification program is: 95 DEG C of denaturations 5min, (95 DEG C of degeneration 15sec, Tm anneal 45sec, and 72 DEG C extend 35sec) ×
40 circulations, concrete Tm is with reference to table 1.
(2) primer screening
After being mixed by each sample cDNA, carrying out 5 times of gradient dilutions as template, after dilution, sample respectively takes 2 μ L and makees template,
Expand with genes of interest primer and reference gene primer respectively, carry out melt curve analysis analysis at 60-95 DEG C, according to expansion simultaneously
Increasing Efficiency is high and the unimodal principle of solubility curve carries out primer screening.
(3) sample Real Time-PCR detection
Take 2 μ L after each sample cDNA 10 times being diluted and make template, enter with genes of interest primer and reference gene primer respectively
Row amplification.Carry out solubility curve analysis at 60-95 DEG C simultaneously.
3, experimental result
Real-time quantitative PCR amplification curve flex point understands, amplification curve entirety collimation is good, shows the amplification effect of each reaction tube
Rate is close, and the limit is flat and nothing raises up now, and exponent phase slope is relatively big, illustrates that amplification efficiency is higher；Sample amplified production is molten
Solution curve is all unimodal, illustrates that amplified production only has one, for specific amplification；Relative quantification formula according to qRT-PCR: 2-ΔΔCt× 100%, icp gene expression in prostate cancer tissue and cancer beside organism.Result shows: qRT-PCR expands
Result is stable, and gene expression in carcinoma of prostate suffers from tissue is less than in cancer beside organism, and result above demonstrates high flux
Transcript profile expresses confluence analysis gene result of down-regulated expression in patients with prostate cancer of data.Concrete condition is shown in Fig. 1.
Prepared by embodiment 3 carcinoma of prostate prognosis evaluation reagent kit
The primer sets obtained based on embodiment 2, assembles the test kit for detecting carcinoma of prostate of the present invention, described
Test kit includes in specific amplified EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1 one or more
The primer sets of gene is as shown in table 1, particularly as follows:
1, test kit includes specific amplification EFCAB10；
2, test kit includes specific amplification EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and THSD1P1.
With the primer of specific amplified house-keeping gene (GAPDH) to as shown in SEQ ID NO:13 and SEQ ID NO:14；Also
Including SYBR Green polymerase chain reaction system, such as PCR buffer, SYBR Green fluorescent dye, dNTPs.Described PCR
The composition of buffer is 25mM KCl, 2.5mM MgCl2, 200mM (NH4)2SO4；Also include prostate normal structure cDNA: make
For negative control and the detection common quantitative PCR detection of sample cDNA, each reaction system uses and detection sample cDNA equal amount.
By the optimization to primer concentration and annealing temperature, finally determine that reaction system is as shown in table 3:
Table 3 PCR reaction system
| Component | Addition |
| SYBR Green polymerase chain reaction system | 12.5μL |
| Forward primer (10 μMs) | 0.5μL |
| Downstream primer (10 μMs) | 0.5μL |
| Template cDNA | 2.0μL |
| Add sterile purified water | To 25 μ L |
Optimum reaction condition is:
95 DEG C of denaturations 5min, (72 DEG C extend 35sec for 95 DEG C of degeneration 15sec, 60 DEG C of annealing 45sec) × 40 circulations,
72 DEG C extend 15min.
The clinical verification of embodiment 4 carcinoma of prostate prognosis evaluation reagent kit
To BJ Union Hospital prostatitis in the 10 example urological surgeries that in October, 2011 accepted for medical treatment between December to 2015
Adenocarcinoma tissue sample is studied, and the surgical tissue of acquisition is prostate cancer tissue.Utilize two kinds of reagent described in embodiment 3
Box detects the relative amount of the expression of corresponding gene in 10 example patients with prostate cancer tissues.Treatment detects patient prostatitis after terminating again
In cancerous tissue, said gene expresses relative amount.Criterion is set to: after treatment, gene expression relative amount is compared with before treatment
Raise less than 10%, it is judged that for failing to respond to any medical treatment；After treatment, the rising compared with before treatment of gene expression relative amount is more than or equal to
10%, it is judged that for treatment effectively, comparing the highest therapeutic effect the best, its assessment result is as shown in table 4.Meanwhile, doctor is according to facing
Bed symptom judges the therapeutic effect of carcinoma of prostate, and result is as shown in table 4.
Test kit assessment carcinoma of prostate efficacy result described in table 4 embodiment 3
As shown in Table 4, in 10 example clinical patients, test kit detects 1 testing result and shows that wherein 5 examples are effective in cure, and remaining is 5 years old
Example is without therapeutic effect, and the judged result in 1 example patient and clinical effectiveness have error wherein；Test kit 2 testing result is that 4 examples have
Treatment effect, this test kit testing result is consistent with clinical judgment result.Drawing accordingly, test kit 2 detects more smart than test kit 1
Really, patients with prostate cancer curative effect can be estimated by the prognosis evaluation reagent kit of carcinoma of prostate of the present invention, and as
The reference value that clinic is provided with.
Although, the present invention is described in detail the most with a general description of the specific embodiments, but
On the basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Cause
This, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to the scope of protection of present invention.
Claims (10)
1. it is used for detecting prostate cancer marker, it is characterised in that described label is selected from following EFCAB10 (NR_
027068.1, lncRNA), MBL1P (NR_002724.2, pseudogene), PPIEL (NR_003929.2, pseudogene),
RAET1K (NR_024045.1, pseudogene), RPL13AP6 (NR_026715.1, pseudogene) and/or THSD1P1
One or more genes in (NC_000013.11, pseudogene).
2. label as claimed in claim 1, it is characterised in that under described gene is all expressed in prostate cancer tissue
Adjust.
3. label application in preparing prostate cancer diagnosis and prognosis product as claimed in claim 1 or 2.
Apply the most as claimed in claim 3, it is characterised in that described diagnosis and prognosis are that diagnosis, curative effect evaluation or transfer are multiple
Send out monitoring.
Apply the most as claimed in claim 3, it is characterised in that described product includes detectable or test kit.
Apply the most as claimed in claim 5, it is characterised in that described detectable includes with fluorescence quantifying PCR method, gene
In chip or RNA order-checking detection testing sample, relative expression's content of said gene carrys out diagnosis of prostate cancer.
Apply the most as claimed in claim 6, it is characterised in that the expression of described detection gene is detection transcript water
Flat.
8. a prostate cancer diagnosis or prognosis evaluation reagent kit, it is characterised in that described test kit includes specific amplification
One or more groups primer sequence in EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1.
9. test kit as claimed in claim 8, it is characterised in that described primer sequence includes: SEQ ID NO.1 and 2；SEQ
ID NO.3 and 4；SEQ ID NO.5 and 6；SEQ ID NO.7 and 8；SEQ ID NO.9 and 10；And/or SEQ ID NO.11 and
12。
10. test kit as claimed in claim 8, it is characterised in that described test kit also include 10 × Buffer, dNTP,
MgCl2, Taq enzyme and SYBR Green fluorescent dye.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610872064.XA CN106148563A (en) | 2016-09-30 | 2016-09-30 | The biomarker of carcinoma of prostate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610872064.XA CN106148563A (en) | 2016-09-30 | 2016-09-30 | The biomarker of carcinoma of prostate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106148563A true CN106148563A (en) | 2016-11-23 |
Family
ID=57340877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610872064.XA Withdrawn CN106148563A (en) | 2016-09-30 | 2016-09-30 | The biomarker of carcinoma of prostate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106148563A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755344A (en) * | 2016-12-01 | 2017-05-31 | 北京致成生物医学科技有限公司 | Molecular marked compound and its application for the diagnosis of cancer of pancreas clinical prognosis |
-
2016
- 2016-09-30 CN CN201610872064.XA patent/CN106148563A/en not_active Withdrawn
Non-Patent Citations (8)
| Title |
|---|
| GENBANK: "NC_000013.11", 《GENBANK》 * |
| GENBANK: "NR_002724.2", 《GENBANK》 * |
| GENBANK: "NR_003929.2", 《GENBANK》 * |
| GENBANK: "NR_024045.1", 《GENBANK》 * |
| GENBANK: "NR_026715.1", 《GENBANK》 * |
| GENBANK: "NR_027068.1", 《GENBANK》 * |
| MYERS JS ET AL.: "Differentally expressed genes and signature pathways of human prostate cancer", 《PLOS ONE》 * |
| SINGH D ET AL.: "Gene expression correlates of clinical prostate cancer behavior", 《CANCER CELL》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755344A (en) * | 2016-12-01 | 2017-05-31 | 北京致成生物医学科技有限公司 | Molecular marked compound and its application for the diagnosis of cancer of pancreas clinical prognosis |
| CN106755344B (en) * | 2016-12-01 | 2020-10-09 | 北京致成生物医学科技有限公司 | Molecular marker for pancreatic cancer clinical prognosis diagnosis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106755344B (en) | Molecular marker for pancreatic cancer clinical prognosis diagnosis and application thereof | |
| CN106350600A (en) | Application of LOC80054 in diagnosis or prognosis of pancreatic cancer | |
| CN106399569A (en) | Application of C2lorf82 in preparation of pancreatic cancer prognosis evaluation products | |
| CN106834470A (en) | Purposes of the miRNA in cancer diagnosing kit is prepared | |
| CN109929932A (en) | Application in blood in two kinds of long-chain non-coding RNA Combining diagnosis esophageal squamous cell carcinomas | |
| CN106755343A (en) | Cancer of pancreas Prognosis molecular marked compound | |
| CN108866187A (en) | One kind long-chain non-coding RNA marker relevant to lung cancer auxiliary diagnosis and its application | |
| CN106381342A (en) | Biomarker used for diagnosis or prognosis of pancreatic cancer | |
| CN108949976A (en) | Purposes of the C12orf70 and/or C17orf107 gene in cancer of pancreas testing product | |
| CN106148562A (en) | For detecting the label of carcinoma of prostate | |
| CN108753980A (en) | A kind of kit for screening of the metastatic screening of the small papillary carcinoma of thyroid gland | |
| CN104531863A (en) | PCA3 gene detection method and primer in human urine | |
| CN106755309A (en) | Application of the molecular marked compound in cancer of pancreas prognosis evaluation product is prepared | |
| AU2017282420A1 (en) | MMP1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method | |
| CN111808963A (en) | Composition for noninvasive screening of early lung cancer, application and kit and sample processing method | |
| CN106148563A (en) | The biomarker of carcinoma of prostate | |
| CN106282366A (en) | A kind of molecular marked compound relevant to carcinoma of prostate and application thereof | |
| CN106367526A (en) | Product for diagnosing prostatic cancer and application thereof | |
| CN110257514A (en) | A kind of new cancer of the esophagus blood miRNA marker and its application | |
| CN106148554A (en) | A kind of mark for carcinoma of prostate detection and the application in test kit thereof | |
| CN106367509A (en) | LOC100128675 serving as molecular marker for detecting prostate cancer and application of molecular marker to diagnostic kit | |
| CN106544430A (en) | A kind of molecular marked compound of detection carcinoma of prostate and its application | |
| CN113637753A (en) | Bladder cancer marker lncRNA TERC based on urine exosome and application thereof | |
| CN106498062A (en) | A kind of product of diagnosis of prostate cancer and its application | |
| CN109563548A (en) | For identifying the in-vitro method of cancer of pancreas or pancreatic intraductal papillary mucinous tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161123 |
|
| WW01 | Invention patent application withdrawn after publication |